Hinova Pharmaceuticals Inc. A (688302.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE1000059F5

Price
32.86 CNY
Market cap
3.25 bn CNY
P/E (2025)
–
P/S (2025)
158.95
Dividend yield
0.00 %
Net margin
-670.51 %
Return on equity (ROE)
-12.91 %
Return on assets (ROA)
-10.48 %

Hinova Pharmaceuticals Inc. A financials

Fiscal year20242025
Revenue366,836.28 CNY20.47 m CNY
Gross profit30,918.28 CNY20.19 m CNY
Operating income-223.00 m CNY-157.36 m CNY
EBIT-198.96 m CNY-136.90 m CNY
Net income-199.50 m CNY-137.25 m CNY
Diluted EPS – continuing operations-2.01 CNY-1.39 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Hinova Pharmaceuticals Inc. A

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HP518, a PROTAC molecule targeting advanced prostate cancer; HP537, a small-molecule anti-tumor drug; HP515, an orally administered which improves liver and blood biochemical indicators; HP570, an orally administered molecular gel degrader targeting VAV1; and HC-X049, a small molecule project with STAT6 target layout. Hinova Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Chengdu, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.